The FDA cleared an investigational new drug application to advance NOV05 in a phase 2 clinical trial in noninfectious anterior uveitis, according to a press release from Novaliq.
The randomized, double-masked EYETAC clinical trial will evaluate NOV05 (tacrolimus ophthalmic solution in EyeSol) in patients with noninfectious anterior uveitis (NIAU), possibly leading to the first topical steroid-free treatment for the inner eye disease. The trial will be conducted at U.S. clinical centers to investigate the safety, tolerability and potential dose-dependent clinical anti-inflammatory effect of two